SURF News and Press, Surface Oncology Inc. From 03/17/21

Surface Oncology ([[SURF]] +3.2%) is on the rise amid rumors that Cathie Wood will talk about the company at a conference scheduled for today.The stock has lost ~4.5% in the year so far, and ARK Genomic Revolution ETF ([[ARKG]] -2.0%) managed by the acclaimed fund manager has a ~0.4% ...

The following slide deck was published by Surface Oncology, Inc. in conjunction with this event. For further details see: Surface Oncology (SURF) Presents At Global Life Sciences Virtual Conference - Slideshow

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing updated preclinical data wil...

Surface Oncology (SURF) has announced a collaboration with Merck (MRK) to evaluate Surface’s investigational antibody therapy SRF388 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).The therapeutic combination will be part of the first-in-human Ph...

AnPac Bio-Medical Science (ANPC) +75% after update on cancer detection system CDAPS.Second Sight Medical Products (EYES) +67%.GT Biopharma (GTBP) +45%.Auris Medical Holding Ltd. (EARS) +24%.Taoping Inc. (TAOP) +10% on launching Blockchain Business Division.AirNet Technology (ANTE) +...

Surface Oncology (SURF): Q4 GAAP EPS of $1.66 beats by $1.31.Revenue of $87.6M (+19809.1% Y/Y) beats by $45.1M.Shares +8.97% PM.Press Release For further details see: Surface Oncology EPS beats by $1.31, beats on revenue

New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA ® (pembrolizumab) in Patients with Solid Tumors CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology ...

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck...

NanoViricides (NNVC) +112% on effectiveness of COVID-19 drug candidates in cell culture studies.Communications Systems (JCS) +38% after entering merger agreement with Pineapple Energy.STRATA Skin Sciences (SSKN) +30% on announcing CEO Transition.CHF Solutions (CHFS) +25%.AgeX T...

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will partic...